---
title: "QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: cost-effectiveness analyses and utility weights"
description: "Published cost-effectiveness analyses and health-state utility weights for QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations, each value quoted from the article: 1 cost-effectiveness analysis and 0 studies reporting utility weights. Analyses: Sirolimus versus supportive care in slow-flow vascular malformations, Australia: Li and Sebaratnam (2024). Every value is a verbatim quote from the primary article it is shown with."
canonical: "https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/cost-effectiveness-analyses"
published: "2026-10-22T07:49:06-04:00"
modified: "2026-10-22T07:49:06-04:00"
---

# QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: cost-effectiveness analyses and utility weights

Published cost-effectiveness analyses and health-state utility weights that a model of this product could cite, adapt, or compare against, grouped by how each article relates to the product and its indication. Every value is quoted from the article it cites, and section 3 lists the searches that found the articles.

<a id="cost-effectiveness-analyses-overview"></a>

## Overview

<a id="cost-effectiveness-analyses-topic-overview-1"></a>

| Item | Detail |
| --- | --- |
| Literature searched | Tufts Medical Center Cost-Effectiveness Analysis Registry, searched October 21, 2026; the queries are listed in section 3. |
| Cost-effectiveness analyses | 1 |
| Studies reporting utility weights | 0 |

<a id="cost-effectiveness-analyses-cost-effectiveness-analyses"></a>

## 1 Cost-effectiveness analyses

<a id="cost-effectiveness-analyses-heading-1.1"></a>

### 1.1 Analyses of QTORIN rapamycin 3.9 percent gel

No evidence found.

<a id="cost-effectiveness-analyses-heading-1.2"></a>

### 1.2 Treatments for the same indication

No evidence found.

<a id="cost-effectiveness-analyses-heading-1.3"></a>

### 1.3 The same disease in other populations or settings

<a id="cost-effectiveness-analyses-topic-1.3-1"></a>

#### Sirolimus versus supportive care in slow-flow vascular malformations, Australia: Li and Sebaratnam (2024)

Relevance: A cost-utility analysis of sirolimus in vascular malformations in Australia, the systemic mTOR inhibitor that section 2 lists for lymphatic malformations.

> “The cost‐utility decision analysis modelled a simulated population of Australian patients aged ≥18 years with slow flow vascular malformations requiring treatment.”
> “In the model, patients were either initiated on sirolimus 1 mg daily or received supportive care.”
> “The analysis employed a decision‐tree model developed with TreeAge Pro Software (Version 2024 R1.1)”
> “Only direct costs were included, as per convention of cost‐utility analyses adopting a healthcare sector perspective.”
> “Costs were reported in August 2024 AU$. Discounting was not applied given the short time horizon.”
> “Over a one‐year time horizon, sirolimus was associated with increased expenditure of AU$2832.80 and a gain of 0.08 QALYs, yielding an ICER of AU$35,410/QALY”
> “The probabilistic sensitivity analyses indicated that relative to the AU$50,000/QALY threshold, base‐case sirolimus was more cost‐effective compared to supportive care in 55.1% of the 10,000 iterations of the Monte Carlo simulation.”

Source: [Li and Sebaratnam (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11629134/)

<a id="cost-effectiveness-analyses-heading-1.4"></a>

### 1.4 Related diseases and analogous treatments

No evidence found.

<a id="cost-effectiveness-analyses-utility-weights"></a>

## 2 Utility weights

<a id="cost-effectiveness-analyses-heading-2.1"></a>

### 2.1 Utility weights from analyses of QTORIN rapamycin 3.9 percent gel

No evidence found.

<a id="cost-effectiveness-analyses-heading-2.2"></a>

### 2.2 Utility weights for the same indication

No evidence found.

<a id="cost-effectiveness-analyses-heading-2.3"></a>

### 2.3 Utility weights for the same disease in other populations or settings

No evidence found.

<a id="cost-effectiveness-analyses-heading-2.4"></a>

### 2.4 Utility weights for related diseases and analogous treatments

No evidence found.

<a id="cost-effectiveness-analyses-search-strategy"></a>

## 3 Search strategy

<a id="cost-effectiveness-analyses-topic-3-1"></a>

| Dataset | Query | Results |
| --- | --- | --- |
| Methods | QTORIN OR rapamycin OR sirolimus | 20 |
| Ratios | "lymphatic malformation" OR "lymphatic malformations" OR lymphangioma OR "cystic hygroma" | 0 |
| Methods | "vascular malformation" OR "vascular malformations" OR "vascular anomalies" OR "lymphatic malformation" | 2 |
| Weights | lymphatic OR lymphangioma OR "vascular malformation" OR "vascular malformations" | 9 |
| Ratios | angiofibroma OR "tuberous sclerosis" OR "topical sirolimus" OR "topical rapamycin" | 4 |
| Ratios | hemangioma OR haemangioma OR "port-wine" OR "port wine" | 0 |
| Ratios | lymphangioleiomyomatosis OR "PIK3CA" OR alpelisib OR "PROS" | 21 |
| Ratios | "epidermolysis bullosa" OR "birch bark" OR "beremagene" | 0 |
| Ratios | sclerotherapy AND (malformation OR cyst) | 0 |

## Related pages
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Terms and abbreviations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations.md)
- [QTORIN rapamycin 3.9 percent gel: Microcystic lymphatic malformations](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/executive-summary.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Product information and disease description](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Clinical evidence](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: Economic information and modeling report](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economics.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: References](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references.md)
- [QTORIN rapamycin 3.9 percent gel in Microcystic lymphatic malformations: prevalence by geography](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence) · [Markdown](https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/prevalence.md)